Evidence map›Paper›PMID 31361789›Full record

ArticlePloS one2019

A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea.

Yufan Chen, Tina R Watson, Steven D Criss, Andrew Eckel, Lauren Palazzo, Deirdre F Sheehan, Chung Yin Kong

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. A Scoping Review on Calibration Methods for Cancer Simulation Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2025
    Article
  3. Natural history models for lung Cancer: A scoping review.Lung cancer (Amsterdam, Netherlands) · 2025
    Article
  4. Article
  5. Review
  6. The geriatric Asia-Pacific oncology nursing imperative.Asia-Pacific journal of oncology nursing · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yufan ChenInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-3501-9807
Tina R WatsonInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Steven D CrissInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Andrew EckelInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Lauren PalazzoInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Deirdre F SheehanInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Chung Yin KongInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0001-6431-7830

Funding

Comparative Modeling of Lung Cancer Prevention and Control PoliciesU01CA199284 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2015 to 2019
$8.4M
NCI NIH HHS U01 CA199284
6 · The paper itself

Abstract

More than 50% of the world's lung cancer cases occur in Asia and more than 20% of cancer deaths in Asia are attributable to lung cancer. The U.S. National Lung Screening Trial has shown that lung cancer screening with computed tomography (CT) can reduce lung cancer deaths. Using the Lung Cancer Policy Model-Asia (LCPM-Asia), we estimated the potential mortality reduction achievable through the implementation of CT-based lung cancer screening in China, Japan, Singapore, and South Korea. The LCPM-Asia was calibrated to the smoking prevalence of each of the aforementioned countries based on published national surveys and to lung cancer mortality rates from the World Health Organization. The calibrated LCPM-Asia was then used to simulate lung cancer deaths under screening and no-screening scenarios for the four countries. Using screening eligibility criteria recommended by the U.S. Centers for Medicare & Medicaid Services (CMS), which are based on age and smoking history, we estimated the lung cancer mortality reduction from screening through year 2040. By 2040, lung cancer screening would result in 91,362 life-years gained and 4.74% mortality reduction in South Korea; 290,325 life-years gained and 4.33% mortality reduction in Japan; 3,014,215 life-years gained and 4.22% mortality reduction in China; and 8,118 life-years gained and 3.76% mortality reduction in Singapore. As for mortality reduction by smoker type, current smokers would have the greatest mortality reduction in each country, ranging from 5.56% in Japan to 6.86% in Singapore. Among the four countries, lung cancer screening under CMS eligibility criteria was most effective in South Korea and least effective in Singapore. Singapore's low smoking prevalence and South Korea's aging population and higher smoking prevalence may partially explain the discrepancy in effectiveness. CT screening was shown to be promising as a means of reducing lung cancer mortality in the four countries.

Indexed as

Computer SimulationHealth PolicyModels, TheoreticalAdultAgedChinaEarly Detection of CancerFemaleHumansJapanLung NeoplasmsMaleMiddle AgedPopulation SurveillancePrognosisRepublic of Korea

Identifiers

PMID31361789
PMCPMC6667161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.